Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrexafungerp - SCYNEXIS

Drug Profile

Ibrexafungerp - SCYNEXIS

Alternative Names: Brexafemme; GSK 5458448; Ibrexafungerp citrate; MK-3118; SCY 078; SCY-078-citrate

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; SCYNEXIS
  • Developer Jiangsu Hansoh Pharmaceutical; Merck & Co; SCYNEXIS
  • Class Alkanes; Amines; Antifungals; Carboxylic acids; Ethers; Glycosides; Heterocyclic compounds; Pyridines; Small molecules; Triazoles; Triterpenes
  • Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis; Invasive candidiasis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Vulvovaginal candidiasis

Highest Development Phases

  • Marketed Vulvovaginal candidiasis
  • Phase III Candidiasis; Invasive candidiasis
  • Phase II Invasive bronchopulmonary aspergillosis
  • Preclinical Mycoses
  • No development reported Pneumocystis pneumonia; Unspecified

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Candidiasis(In volunteers) in South Africa (IV)
  • 13 Nov 2023 Scynexis completes a phase III VANQUISH trial in Vulvovaginal candidiasis (In adults, In the elderly, Treatment-experienced) in USA (PO) (NCT05399641)
  • 13 Nov 2023 The phase III MARIO trial for Candidiasis was placed on clinical hold due to this potential cross-contamination in Bulgaria, Spain, South Africa, Greece, Belgium, USA (PO) (NCT05178862)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top